These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7809951)

  • 1. Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model.
    Robertson MJ; Dougall IG; Harper D; McKechnie KC; Leff P
    Trends Pharmacol Sci; 1994 Oct; 15(10):364-9. PubMed ID: 7809951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of tachyphylaxis to angiotensin II in rabbit isolated aorta by the angiotensin AT1 receptor antagonist, losartan.
    Robertson MJ; Wragg A; Clark KL
    Regul Pept; 1994 Feb; 50(2):137-45. PubMed ID: 8190915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.
    Dickinson KE; Cohen RB; Skwish S; Delaney CL; Serafino RP; Poss MA; Gu Z; Ryono DE; Moreland S; Powell JR
    Br J Pharmacol; 1994 Sep; 113(1):179-89. PubMed ID: 7812609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist.
    Lee SH; Jung YS; Lee BH; Yun SI; Yoo SE; Shin HS
    J Cardiovasc Pharmacol; 1999 Mar; 33(3):367-74. PubMed ID: 10069670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that [Sar1]angiotensin II behaves differently from angiotensin II at angiotensin AT1 receptors in rabbit aorta.
    Liu YJ
    Eur J Pharmacol; 1993 Apr; 235(1):9-15. PubMed ID: 8519284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor.
    Ojima M; Inada Y; Shibouta Y; Wada T; Sanada T; Kubo K; Nishikawa K
    Eur J Pharmacol; 1997 Jan; 319(1):137-46. PubMed ID: 9030909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy.
    Eberhardt RT; Kevak RM; Kang PM; Frishman WH
    J Clin Pharmacol; 1993 Nov; 33(11):1023-38. PubMed ID: 8300885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.
    Vauquelin G; Morsing P; Fierens FL; De Backer JP; Vanderheyden PM
    Biochem Pharmacol; 2001 Feb; 61(3):277-84. PubMed ID: 11172731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.
    Fierens FL; Vanderheyden PM; De Backer JP; Vauquelin G
    Eur J Pharmacol; 1999 May; 372(2):199-206. PubMed ID: 10395100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations.
    Zhang J; Pfaffendorf M; Zhang JS; Van Zwieten PA
    Eur J Pharmacol; 1994 Feb; 252(3):337-40. PubMed ID: 8162955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of valsartan to mammalian angiotensin AT1 receptors.
    de Gasparo M; Whitebread S
    Regul Pept; 1995 Nov; 59(3):303-11. PubMed ID: 8577935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the AT1 angiotensin II receptor expressed in guinea pig liver.
    García-Sáinz JA; Martínez-Alfaro M; Romero-Avila MT; González-Espinosa C
    J Endocrinol; 1997 Jul; 154(1):133-8. PubMed ID: 9246947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.
    Robertson MJ; Barnes JC; Drew GM; Clark KL; Marshall FH; Michel A; Middlemiss D; Ross BC; Scopes D; Dowle MD
    Br J Pharmacol; 1992 Dec; 107(4):1173-80. PubMed ID: 1467838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of losartan (DuP 753)-induced angiotensin II receptor antagonism by PD123177 in rats.
    Wong PC; Christ DD; Timmermans PB
    Eur J Pharmacol; 1992 Sep; 220(2-3):267-70. PubMed ID: 1425998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.
    Haddad G; Amiri F; Garcia R
    Regul Pept; 1997 Jan; 68(2):111-7. PubMed ID: 9110382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II receptors involved in the enhancement of noradrenergic transmission in the caudal artery of the spontaneously hypertensive rat.
    Cox SL; Story DF; Ziogas J
    Br J Pharmacol; 1996 Nov; 119(5):965-75. PubMed ID: 8922747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats.
    Linz W; Henning R; Schölkens BA
    J Hypertens Suppl; 1991 Dec; 9(6):S400-1. PubMed ID: 1840203
    [No Abstract]   [Full Text] [Related]  

  • 18. A two-state model of antagonist-AT1 receptor interaction: further support by binding studies at low temperature.
    Verheijen I; De Backer JP; Vanderheyden P; Vauquelin G
    Biochem Pharmacol; 2003 Apr; 65(8):1339-41. PubMed ID: 12694874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Losartan: the first angiotensin receptor antagonist in clinical use.
    Beevers DG
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S1. PubMed ID: 8583475
    [No Abstract]   [Full Text] [Related]  

  • 20. The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism.
    Feng YH; Noda K; Saad Y; Liu XP; Husain A; Karnik SS
    J Biol Chem; 1995 May; 270(21):12846-50. PubMed ID: 7759541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.